Orbus Therapeutics, Inc.
2 clinical trials · Sponsor
◉ Watch Orbus Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma (NCT05879367) | Orbus Therapeutics, Inc. | 2023-07-24 |
Track Orbus Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.